1. Home
  2. BIOA vs TEAF Comparison

BIOA vs TEAF Comparison

Compare BIOA & TEAF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • BIOA
  • TEAF
  • Stock Information
  • Founded
  • BIOA 2015
  • TEAF 2017
  • Country
  • BIOA United States
  • TEAF United States
  • Employees
  • BIOA N/A
  • TEAF N/A
  • Industry
  • BIOA Biotechnology: Pharmaceutical Preparations
  • TEAF Trusts Except Educational Religious and Charitable
  • Sector
  • BIOA Health Care
  • TEAF Finance
  • Exchange
  • BIOA Nasdaq
  • TEAF Nasdaq
  • Market Cap
  • BIOA 162.0M
  • TEAF 174.8M
  • IPO Year
  • BIOA 2024
  • TEAF N/A
  • Fundamental
  • Price
  • BIOA $4.49
  • TEAF $11.73
  • Analyst Decision
  • BIOA Hold
  • TEAF
  • Analyst Count
  • BIOA 3
  • TEAF 0
  • Target Price
  • BIOA $18.00
  • TEAF N/A
  • AVG Volume (30 Days)
  • BIOA 161.8K
  • TEAF 56.1K
  • Earning Date
  • BIOA 03-14-2025
  • TEAF 01-01-0001
  • Dividend Yield
  • BIOA N/A
  • TEAF 9.20%
  • EPS Growth
  • BIOA N/A
  • TEAF N/A
  • EPS
  • BIOA N/A
  • TEAF N/A
  • Revenue
  • BIOA N/A
  • TEAF N/A
  • Revenue This Year
  • BIOA N/A
  • TEAF N/A
  • Revenue Next Year
  • BIOA N/A
  • TEAF N/A
  • P/E Ratio
  • BIOA N/A
  • TEAF N/A
  • Revenue Growth
  • BIOA N/A
  • TEAF N/A
  • 52 Week Low
  • BIOA $3.85
  • TEAF $11.11
  • 52 Week High
  • BIOA $26.62
  • TEAF $13.30
  • Technical
  • Relative Strength Index (RSI)
  • BIOA N/A
  • TEAF 32.45
  • Support Level
  • BIOA N/A
  • TEAF $11.97
  • Resistance Level
  • BIOA N/A
  • TEAF $12.09
  • Average True Range (ATR)
  • BIOA 0.00
  • TEAF 0.10
  • MACD
  • BIOA 0.00
  • TEAF -0.03
  • Stochastic Oscillator
  • BIOA 0.00
  • TEAF 13.48

About BIOA BioAge Labs Inc. Common Stock

Bioage Labs Inc is a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases, such as obesity, by targeting the biology of human aging. Its focus is metabolic disease, one of the greatest healthcare challenges. Its Products are Azelaprag (BGE-105), an apelin receptor APJ agonist that increases weight loss and improves body composition combined with incretin drugs. and BGE-100 is targeting metabolic diseases and neuroinflammation.

About TEAF Ecofin Sustainable and Social Impact Term Fund

Tortoise Essential Assets Income Term is a US-based non-diversified, closed-end management investment company. Its investment objective is to provide common shareholders with a high level of total return with an emphasis on current distributions.

Share on Social Networks: